Embera NeuroTherapeutics Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A2

  • Latest Deal Amount
  • $20K

  • Investors
  • 14

Embera NeuroTherapeutics General Information

Description

Operator of a pharmaceutical company intended to develop novel treatments to potentially treat a range of addictions. The company's medication reduces the cravings and loss of control that drive addiction by targeting multiple pathways, to maximize potential efficacy more than either drug used alone, enabling patients to abstain from smoking and drug use.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 365 Boston Post Road
  • Suite 212
  • Sudbury, MA 01776
  • United States
+1 (978) 000-0000

Embera NeuroTherapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Embera NeuroTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC (Series A2) 11-Sep-2020 $20K 000.00 Completed Generating Revenue
11. Later Stage VC (Series B) 01-Aug-2020 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B) 09-Nov-2016 00.00 000.00 0000 Completed Clinical Trials - Phase 1
9. Grant 01-Aug-2016 00.000 0000 Completed Clinical Trials - Phase 1
8. Grant 26-Jul-2016 000.00 0000 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A2) 29-Sep-2015 00.000 0000 000.00 Completed Generating Revenue
6. Accelerator/Incubator 05-Aug-2015 00.00 Completed Generating Revenue
5. Grant 01-Jul-2014 00.00 00.00 Completed Generating Revenue
4. Later Stage VC (Series A2) 15-Aug-2011 $4.5M $9.5M Completed Startup
3. Early Stage VC (Series A) 03-Sep-2008 $3M $4.96M Completed Startup
To view Embera NeuroTherapeutics’s complete valuation and funding history, request access »

Embera NeuroTherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series A2 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 1,357,100 $0.001000 $0.06 $1 $1 1x $1 3.74%
To view Embera NeuroTherapeutics’s complete cap table history, request access »

Embera NeuroTherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a pharmaceutical company intended to develop novel treatments to potentially treat a range of addictions. Th
Drug Discovery
Sudbury, MA
4 As of 2023
000.00
00000000000 000.00

000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit i
000000000000000
South San Francisco, CA
00 As of 0000
00000
0000000000.

00000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita
0000000000000
Cambridge, MA
00 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embera NeuroTherapeutics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Achaogen Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
Spero Therapeutics Formerly VC-backed Cambridge, MA 00 00000 0000000000 00000
You’re viewing 2 of 2 competitors. Get the full list »

Embera NeuroTherapeutics Patents

Embera NeuroTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200360400-A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease Inactive 19-May-2017 0000000000
US-11179377-B2 Pharmaceutical compositions and uses thereof Active 10-Mar-2017 0000000000 000
EP-3592350-A4 Pharmaceutical compositions and uses thereof Pending 10-Mar-2017 0000000000 0
EP-3592350-A1 Pharmaceutical compositions and uses thereof Pending 10-Mar-2017 0000000000
US-20200054615-A1 Pharmaceutical compositions and uses thereof Active 10-Mar-2017 A61K9/1611
To view Embera NeuroTherapeutics’s complete patent history, request access »

Embera NeuroTherapeutics Executive Team (11)

Name Title Board Seat Contact Info
Gary Connor Chief Operating Officer & Vice President of Clinical Operations
Julie Straub Ph.D Vice President, CMC and Nonclinical Development
Ann Robbins Ph.D Vice President, Regulatory Affairs
Bruce McCarthy MD Chief Medical Officer
Ross Barrett JD Chairman
You’re viewing 5 of 11 executive team members. Get the full list »

Embera NeuroTherapeutics Board Members (8)

Name Representing Role Since
Dennis Purcell Self Board Member 000 0000
Franz Hefti Ph.D Self Board Member 000 0000
John Beaird Self Board Member 000 0000
Joseph Lovett Louisiana Funds Board Member 000 0000
Ross Barrett JD Self Chairman 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Embera NeuroTherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Embera NeuroTherapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seven Funds Venture Capital Minority 000 0000 000000 0
NO/LA Angel Network Angel Group Minority 000 0000 000000 0
Technomark Life Sciences Venture Capital Minority 000 0000 000000 0
ROSE RESEARCH CENTER, LLC Corporation 000 0000 000000 0
HRA Pharma Corporation Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »